Skip to main content

Research Repository

Advanced Search

Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial

Bath, Philip M.W.; Appleton, Jason P.; Beridze, M.; Christensen, Hanne; Dineen, Robert A.; Duley, Lelia; England, Timothy J.; Heptinstall, Stan; James, Marilyn; Krishnan, Kailash; Markus, H.S.; Pocock, Stuart J.; Ranta, A.; Robinson, Thompson G.; Flaherty, Katie; Scutt, Polly; Venables, G.; Woodhouse, Lisa J.; Sprigg, Nikola

Baseline characteristics of the 3,096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial Thumbnail


Stroke Association Professor of Stroke Medicine

Jason P. Appleton

M. Beridze

Hanne Christensen

Robert A. Dineen

Lelia Duley

Timothy J. England

Stan Heptinstall

Professor of Health Economics

Kailash Krishnan

H.S. Markus

Stuart J. Pocock

A. Ranta

Thompson G. Robinson

Katie Flaherty

Polly Scutt

G. Venables

Lisa J. Woodhouse

Professor of Stroke Medicine


Background: The risk of recurrence following ischaemic stroke (IS) or transient ischaemic attack (TIA) is highest immediately after the event. Antiplatelet agents are effective in reducing the risk of recurrence and two agents are superior to one in the early phase after ictus.

Design: The Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial was an international multicentre prospective randomised open-label blinded-endpoint trial that assessed the safety and efficacy of short-term intensive antiplatelet therapy with three agents (combined aspirin, clopidogrel and dipyridamole) as compared with guideline treatment in acute IS or TIA. The primary outcome was stroke recurrence and its severity, measured using the modified Rankin Scale at 90 days. Secondary outcomes included recurrent vascular events, functional measures (cognition, disability, mood, quality of life) and safety (bleeding, death, serious adverse events). Data are number (%) or mean (standard deviation, SD).

Results: Recruitment ran from April 2009 to March 2016. 3,096 patients were recruited from 106 sites in 4 countries (Denmark 1.6%, Georgia 2.7%, New Zealand 0.2%, UK 95.4%). Randomisation characteristics included: age 69.0 (10.1) years; male 1945 (62.8%); time onset to randomisation 29.4 (11.9) hours; stroke severity (National Institutes for Health Stroke Scale) 2.8 (3.6); blood pressure 143.5 (18.2)/79.5 (11.4) mmHg; IS 2143 (69.2%), TIA 953 (30.8%).

Conclusion: TARDIS was a large trial of intensive/triple antiplatelet therapy in acute IS and TIA, and included participants from four predominantly Caucasian countries who were representative of patients in many western stroke services.

Journal Article Type Article
Acceptance Date Sep 21, 2016
Online Publication Date Nov 4, 2016
Publication Date Jul 1, 2017
Deposit Date Nov 21, 2016
Publicly Available Date Nov 21, 2016
Journal International Journal of Stroke
Print ISSN 1747-4930
Electronic ISSN 1747-4949
Publisher SAGE Publications
Peer Reviewed Peer Reviewed
Volume 12
Issue 5
Pages 524-538
Keywords Acute ischaemic stroke, Acute transient ischaemic attack (TIA), Aspirin, Bleeding, Clopidogrel, Dipyridamole, Randomised controlled trial
Public URL
Publisher URL


You might also like

Downloadable Citations